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Summary
Streptomycin has been used in pregnant patients
for more than 30 years. Some doubt, however, still
exists with regard to its effects on the ear of the
unborn child. Thirty-three children whose mothers
had received streptomycin during pregnancy were
followed up and their hearing tested. A minor
degree of hearing loss which could possibly be due
to the action of streptomycin was found in only 2
children.
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They found normal hearing and vestibular function in 2 children
whose mothers had received SM and had themselves developed
loss of vestibular function. Since then at least 8 reports of
deafness in children whose mothers received SM or
dihydrostreptomycin (DHSM) in pregnancy have appeared
(Table I). Most of these children had marked loss ofhearing and
in 4 cases vestibular function was affected.
In contrast, follow-up of groups of children at risk from the
use of SM and DHSM in pregnancy (Table I1) has tended to
show that loss of hearing, when found, is high-tone and outside
the speech frequencies. Likewise vestibular dysfunction, when
found, has not been serious and is not usually associated with any
clinical disability. Despite these reports, the number of children
so far followed up has been insufficient to permit any defmite
conclusion whether SI\1 is in fact toxic to the fetal inner ear when
given to the mother in pregnancy.
A pregnant patient may present with active tuberculosis
requiring treatment. Despite the development of a number of
new antituberculosis drug, streptomycin sulphate (SM,)
continues to play an important part in the first-line treatment of
tuberculosis and is often used during pregnancy,
SM is known to have toxic effects upon the inner ear, and it has
been suggested that the unborn child might be more susceptible
to these than the adult. I SM crosses the placenta/·3 and le\'els up
to 50% of those found in the mother's circulation ha\'e been
reached in the feral circulation,.J Fetal inner ear damage
following the use of SM in pregnancy is therefore possible.
\X-'atson and Stow; were the first to report the follow-up of
children whose mothers had received SM during pregnancy.
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Subjects and methods
During the period 1960-1976, 82 Cape Coloured and 5 White
patients received SM during pregnancy while being treated for
tuberculosis at the City Hospital for Infectious Diseases, Green
Point, Cape Town. S1\1 was given to these patients for at least I
month at a dosage of I g/d. Up to 1974, SM was without
exception combined \\'ith para-aminosalicylic acid and isoniazid.
Since 1974, other drugs - ethionamide, rifampicin and
ethambutol - have, when indicated, been used to supplement
S,1\1.
It prO\'ed possible to trace 30 of the 87 mothers who had been
treated and 33 children. They were asked to attend the
Department of Otorhinolaryngology at Groote Schuur Hospital
for hearing tests and routine ear, nose and throat examination;
the children's ages at the time ofexamination ranged from I to 16
years.
Results
The results of the hearing tests are set out in Table Ill, together
with details of treatment and the stage of pregnancy during
Nature of defects
Absent otopalpebral reflex but normal
caloric responses
Loss of hearing
Severe bilateral sensorineural hearing loss
and deficient vestibular function
Severe bilateral sensorineural hearing loss
and deficient vestibular function
Both severe bilateral sensory hearing loss
and deficient vestibular function
Congenital deaf-mutism
Profound bilateral deafness
SM
SM
SM
SM
SM
DHSM
22
TABLE I. STREPTOMYCIN OTOTOXICITY IN THE UNBORN CHILD - CASE REPORTS
No. of Affected Drug
cases children used
1 1 SM
Authors
Moulonguet (quoted by Kreibich7)'
Bolletti and Croat08
Robinson and Cambon lO
Kern9
Le Roux 6 '
Khanna and Bhatia"
Sellars et al. 12
In 1954 Krelblch reviewed 37 reported cases In which streptomycin had been admlnlstE~reddunng pregnancy. Two of the children were found IQ be deaf and are the cases of
Le Roux and Moulonguel mentioned above.
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TABLE 11. STREPTOMYCIN OTOTOXICITY IN THE UNBORN CHILD - FOLLOW-UP OF GROUPS OF CHILDREN AT RISK
No. of affected
children
Authors
Rebattu et al. 13
Lenzi and Ancona 14
Conway and Birt '5
Rasmussen '6
Varpela et a/H
Ganguin and Rempt18
No. of
cases
6
10
17
36
40
44
Loss of
hearing
1
3
4
2
5
Vestibular
dysfunction
1
o
6
o
2
o
Drug
used
SM
DHSM
SM
SM
DHSM
SM
DHSM
SM
DHSM
SM
Nature of defects
High-tone hearing loss in both cases
No clinical disability of hearing or vestibular
function
Mild bilateral sensorineural hearing loss
Unilateral high-tone loss outside of speech
frequencies in all cases. No clinical ves-
tibular dysfunction
High-tone unilateral hearing loss in case,
bilateral high-tone loss, probably a result
of noise trauma, in the other
High-tone sensorineural loss .. Possible
vestibular dysfunction in 1 child
Only higher frequencies outside normal
speech frequencies affected
In 1963 Grande and Vespa 19 reported a series of 14 children whose mothers had been treated with DHSM. Seven were found to have a degree of deafness within the speech frequencies.
TABLE Ill. STREPTOMYCIN OTOTOXICITY IN THE UNBORN CHILD - RESULTS OF FOLLOW-UP OF 33 CHILDREN AND 30 MOTHERS
Case Details of treatment Other Age at testing (yrs) Result of hearing test
No. Duration Stage of pregnancy drugs Mother Child Mother Child
(mo.)
3 3rd trimester INH, 42 16 Normal Normal
PAS
2 11/ 2 3rd trimester INH, 48 14 Perceptive loss in right ear Slight bilateral high-tone loss
PAS (30-40 db)
3-7 1-5
'
/ 2 Various trimesters INH, 35-44 11-13 Normal Normal
PAS
8 6 2nd and 3rd trimesters INH, 35 11 Bilateral conductive loss, right Right normal, left slight high-
PAS greater than left Previous right tone loss
radical mastoidectomy
9 4 2nd and 3rd trimesters INH, 29 10 Normal Normal
PAS
10 6 2nd and 3rd trimesters INH, 44 10 High-tone loss left and right Normal
PAS
11-21 1-6 Various trimesters INH, 24-31' 5-8 Normal Normal
PAS
22 5 2nd and 3rd trimesters INH, 31 4 Normal Slight bilateral conductive loss.
PAS Right tympanic perforation,
left tympanosclerosis
23 4 2nd and 3rd trimesters INH, 24 4 Normal Normal
PAS
24-26 2
'
/ 2-3 Various trimesters INH, 25-46 4 Normal Normal
ETH
29-31 1-4 Various trimesters INH, 19-26 Normal Normal
EMB
32 2 3rd trimester INH, 26 Not tested Normal
RMP,
EMB
33 4 2nd and 3rd trimesters INH, 20 Normal Normal
EMB
34 No streptomycin INH, 29 21/ 2 Slight bilateral high-tone Slight bilateral high-tone
PZA, hearing loss hearing loss
ETH,
EMB,
RMP
. Two mothers in this group had died.
INH = isoniazid: PAS = para-aminosalicylic acid: ETH = ethionamide: EMS = ethambutol: AMP = rifampicin: PZA = pyrazinamide.
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which SM had been given. Three mothers who had received SM
and 3 children were found to have defective hearing. In 2 cases
(cases 2 and 8) both mother and child were affected.
In case 2 the bilateral deafness of mother and child could be
ascribed to the action of SM, but in case 8, while the child's
unilateral defective hearing could have been due to SM, the
mother's bilateral conductive hearing loss could not. SM could
also be implicated in the bilateral high-tone loss ofhearing ofthe
mother in case 10, but could not have been the cause of hearing
loss in the child in case 22, who had evidence of past middle ear
disease.
Sixteen mothers had been treated during the 3rd trimester of
pregnancy. One of the children in this group had slight bilateral
high-tone hearing loss (case 2). Thirteen mothers had been
treated in the 2nd and 3rd trimesters; I of their children had
slight unilateral high-tone loss of hearing (case 8). One mother
was treated in the Isttrimesteronly, 2 mothers in the 1st and 2nd
trimesters and I mother for 7 months from the 1st trimester to
the 3rd trimester; none oftheir children was found to suffer from
deafness which could be ascribed to SM.
Discussion
The results of this follow-up do not differ greatly from those of
previous surveys, and confirm that SM can possibly cause
deafness in the unborn child when given to the mother in
pregnancy. However, as in previous surveys, what deafness was
found in the children was high-tone and outside the speech
frequencies; the children in question were not handicapped by
their defect.
Sensitivity to the ototoxic action of SM is subject to a wide
range of individual variability, and in some cases has been found
to be a familial trait.20.21 It is therefore of interest to note that one
mother and child pair in this survey (case 2) was found to have a
degree of deafness which could possibly be ascribed to a familial
susceptibility to the action of SM.
Vestibular function was not tested in these children, but none
of them was noted to have any obvious disability. In a series of 17
children Conway and Birt'S found 6 who had abnormal
vestibular responses on caloric testing but not complete loss of
labyrinthine function. None of the children experienced any
disability in day-to-day activities. Rasmussen 16 followed up 16
children and found them all to have normal vestibular function,
while in a series of 34 children Varpela et al. 17 found only 2 with
vestibular defects. One of these was thought to have a degree of
clinical disability.
The inadvisability of anributing abnormalities found in a
survey such as this to the action of SM, or any other drug, is well
illustrated by a further mother and child pair who were
inadvertently asked to attend for testing (case 34). Both were
found to suffer from high-tone deafness, but SM had not been
used at all in the treatment of the mother's tuberculosis. She had
received isoniazid, pyrazinamide, ethionamide, ethambutol and
rifampicin.
On present evidence it would therefore appear that, when
given to the mother in pregnancy in acceptable doses, SM can
possibly cause a minor degree of deafness in the unborn child.
The deafness, however, is usually high-tone and outside the
speech frequencies. While the decision to use any drug in
pregnancy should not be lightly taken, it would seem that SM
may be used subject to the same considerations as would apply in
a non-pregnant patient - it should therefore not be used in the
presence of impaired renal function, and the performance of
monthly audiograms is desirable to detect the first signs of
ototoxicity, at which stage the drug should be withdrawn.
With regard to other possible toxic or teratogenic effects, SM
has now been used in pregnancy for more than 30 years and in
reports and reviews by a number of authors there has been very
little suggestion that it has any toxic or teratogenic effects upon
the fetus, other than its possible effect upon the inner ear, even
when given in the early stages of pregnancy.22-28 -
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